Fabio Silvio Taccone1, Nina Van Goethem2, Robby De Pauw2, Xavier Wittebole3, Koen Blot2, Herman Van Oyen2,4, Tinne Lernout2, Marion Montourcy2, Geert Meyfroidt5, Dominique Van Beckhoven2. 1. Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium. 2. Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium. 3. Department of Intensive Care, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium. 4. Department of Public Health and Primary Care, University of Gent, Gent, Belgium. 5. Department of Intensive Care Medicine, University of Leuven, Leuven, Belgium.
Abstract
BACKGROUND: Several studies have investigated the predictors of in-hospital mortality for COVID-19 patients who need to be admitted to the Intensive Care Unit (ICU). However, no data on the role of organizational issues on patients' outcome are available in this setting. The aim of this study was therefore to assess the role of surge capacity organisation on the outcome of critically ill COVID-19 patients admitted to ICUs in Belgium. METHODS: We conducted a retrospective analysis of in-hospital mortality in Belgian ICU COVID-19 patients via the national surveillance database. Non-survivors at hospital discharge were compared to survivors using multivariable mixed effects logistic regression analysis. Specific analyses including only patients with invasive ventilation were performed. To assess surge capacity, data were merged with administrative information on the type of hospital, the baseline number of recognized ICU beds, the number of supplementary beds specifically created for COVID-19 ICU care and the "ICU overflow" (i.e. a time-varying ratio between the number of occupied ICU beds by confirmed and suspected COVID-19 patients divided by the number of recognized ICU beds reserved for COVID-19 patients; ICU overflow was present when this ratio is ≥ 1.0). FINDINGS: Over a total of 13,612 hospitalised COVID-19 patients with admission and discharge forms registered in the surveillance period (March, 1 to August, 9 2020), 1903 (14.0%) required ICU admission, of whom 1747 had available outcome data. Non-survivors (n = 632, 36.1%) were older and had more frequently various comorbid diseases than survivors. In the multivariable analysis, ICU overflow, together with older age, presence of comorbidities, shorter delay between symptom onset and hospital admission, absence of hydroxychloroquine therapy and use of invasive mechanical ventilation and of ECMO, was independently associated with an increased in-hospital mortality. Similar results were found in in in the subgroup of invasively ventilated patients. In addition, the proportion of supplementary beds specifically created for COVID-19 ICU care to the previously existing total number of ICU beds was associated with increased in-hospital mortality among invasively ventilated patients. The model also indicated a significant between-hospital difference in in-hospital mortality, not explained by the available patients and hospital characteristics. INTERPRETATION: Surge capacity organisation as reflected by ICU overflow or the creation of COVID-19 specific supplementary ICU beds were found to negatively impact ICU patient outcomes. FUNDING: No funding source was available for this study.
BACKGROUND: Several studies have investigated the predictors of in-hospital mortality for COVID-19 patients who need to be admitted to the Intensive Care Unit (ICU). However, no data on the role of organizational issues on patients' outcome are available in this setting. The aim of this study was therefore to assess the role of surge capacity organisation on the outcome of critically ill COVID-19 patients admitted to ICUs in Belgium. METHODS: We conducted a retrospective analysis of in-hospital mortality in Belgian ICU COVID-19 patients via the national surveillance database. Non-survivors at hospital discharge were compared to survivors using multivariable mixed effects logistic regression analysis. Specific analyses including only patients with invasive ventilation were performed. To assess surge capacity, data were merged with administrative information on the type of hospital, the baseline number of recognized ICU beds, the number of supplementary beds specifically created for COVID-19 ICU care and the "ICU overflow" (i.e. a time-varying ratio between the number of occupied ICU beds by confirmed and suspected COVID-19 patients divided by the number of recognized ICU beds reserved for COVID-19 patients; ICU overflow was present when this ratio is ≥ 1.0). FINDINGS: Over a total of 13,612 hospitalised COVID-19 patients with admission and discharge forms registered in the surveillance period (March, 1 to August, 9 2020), 1903 (14.0%) required ICU admission, of whom 1747 had available outcome data. Non-survivors (n = 632, 36.1%) were older and had more frequently various comorbid diseases than survivors. In the multivariable analysis, ICU overflow, together with older age, presence of comorbidities, shorter delay between symptom onset and hospital admission, absence of hydroxychloroquine therapy and use of invasive mechanical ventilation and of ECMO, was independently associated with an increased in-hospital mortality. Similar results were found in in in the subgroup of invasively ventilated patients. In addition, the proportion of supplementary beds specifically created for COVID-19 ICU care to the previously existing total number of ICU beds was associated with increased in-hospital mortality among invasively ventilated patients. The model also indicated a significant between-hospital difference in in-hospital mortality, not explained by the available patients and hospital characteristics. INTERPRETATION: Surge capacity organisation as reflected by ICU overflow or the creation of COVID-19 specific supplementary ICU beds were found to negatively impact ICU patient outcomes. FUNDING: No funding source was available for this study.
Authors: Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos Journal: JAMA Date: 2020-05-26 Impact factor: 56.272
Authors: Peter Horby; Marion Mafham; Louise Linsell; Jennifer L Bell; Natalie Staplin; Jonathan R Emberson; Martin Wiselka; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Tony Whitehouse; Timothy Felton; John Williams; Jakki Faccenda; Jonathan Underwood; J Kenneth Baillie; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Wei Shen Lim; Alan Montgomery; Kathryn Rowan; Joel Tarning; James A Watson; Nicholas J White; Edmund Juszczak; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-10-08 Impact factor: 91.245
Authors: Shadman Aziz; Yaseen M Arabi; Waleed Alhazzani; Laura Evans; Giuseppe Citerio; Katherine Fischkoff; Jorge Salluh; Geert Meyfroidt; Fayez Alshamsi; Simon Oczkowski; Elie Azoulay; Amy Price; Lisa Burry; Amy Dzierba; Andrew Benintende; Jill Morgan; Giacomo Grasselli; Andrew Rhodes; Morten H Møller; Larry Chu; Shelly Schwedhelm; John J Lowe; Du Bin; Michael D Christian Journal: Intensive Care Med Date: 2020-06-08 Impact factor: 41.787
Authors: Nina Van Goethem; Pui Yan Jenny Chung; Marjan Meurisse; Mathil Vandromme; Laurane De Mot; Ruben Brondeel; Veerle Stouten; Sofieke Klamer; Lize Cuypers; Toon Braeye; Lucy Catteau; Louis Nevejan; Joris A F van Loenhout; Koen Blot Journal: Viruses Date: 2022-06-14 Impact factor: 5.818
Authors: José L Peñalvo; Els Genbrugge; Elly Mertens; Diana Sagastume; Marianne A B van der Sande; Marc-Alain Widdowson; Dominique Van Beckhoven Journal: BMJ Open Date: 2021-09-16 Impact factor: 3.006
Authors: Edward Litton; Sue Huckson; Shaila Chavan; Tamara Bucci; Anthony Holley; Evan Everest; Sean Kelly; Steven McGloughlin; Johnny Millar; Nhi Nguyen; Mark Nicholls; Paule Secombe; David Pilcher Journal: Med J Aust Date: 2021-10-22 Impact factor: 12.776
Authors: Jose Victor Jimenez; Antonio Olivas-Martinez; Fausto Alfredo Rios-Olais; Frida Ayala-Aguillón; Fernando Gil-López; Mario Andrés de Jesús Leal-Villarreal; Juan José Rodríguez-Crespo; Juan C Jasso-Molina; Linda Enamorado-Cerna; Francisco Eduardo Dardón-Fierro; Bernardo A Martínez-Guerra; Carla Marina Román-Montes; Pedro E Alvarado-Avila; Noé Alonso Juárez-Meneses; Luis Alberto Morales-Paredes; Adriana Chávez-Suárez; Irving Rene Gutierrez-Espinoza; María Paula Najera-Ortíz; Marina Martínez-Becerril; María Fernanda Gonzalez-Lara; Alfredo Ponce de León-Garduño; José Ángel Baltazar-Torres; Eduardo Rivero-Sigarroa; Guillermo Dominguez-Cherit; Robert C Hyzy; David Kershenobich; José Sifuentes-Osornio Journal: Crit Care Explor Date: 2022-03-28
Authors: Dieter Mesotten; Daniek A M Meijs; Bas C T van Bussel; Björn Stessel; Jannet Mehagnoul-Schipper; Anisa Hana; Clarissa I E Scheeren; Ulrich Strauch; Marcel C G van de Poll; Chahinda Ghossein-Doha; Wolfgang F F A Buhre; Johannes Bickenbach; Margot Vander Laenen; Gernot Marx; Iwan C C van der Horst Journal: Crit Care Med Date: 2022-04-01 Impact factor: 9.296